Treatment.com AI's Rocket Doctor Expands US Reach and Drives New Growth Through Virtual ER Innovation

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatmen.com AI.
2. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
3.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
4. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) and its wholly owned subsidiary, Rocket Doctor, welcomed recent remarks by U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., who voiced strong support for expanding telehealth and artificial intelligence (AI) tools in the American healthcare system. During a House Appropriations Committee Budget Hearing on May 14, Secretary Kennedy advocated for AI-driven diagnostics to reduce emergency room visits and improve access to home-based care. 

"We are going to dramatically revolutionize the availability of telehealth and AI so that people can avoid emergency rooms by getting treated at home," Kennedy said, citing technologies that can diagnose strep throat using smartphone cameras. 

Secretary Kennedy's comments align with Rocket Doctor's model, which enables physicians to launch and manage virtual practices, most recent examples being through new partnerships in New York and California. Rocket Doctor is focused on serving Medicare and Medicaid patients in both urban and rural areas, including the use of AI-powered diagnostic tools and Bluetooth-enabled medical devices. According to the company, its virtual ER services alone have helped more than 4,000 patients avoid ER visits, as exemplified through its partnership with Georgian Bay General Hospital in Ontario. 

"Secretary Kennedy's remarks validate what we've been building," said Dr. William Cherniak, Founder and CEO of Rocket Doctor, in the news release. "Our system is designed to address the problem of patients using more costly emergency services when care could be delivered safely at home."

Rocket Doctor was recently named Clinical Innovator of the Year by the American Telemedicine Association. Its parent company, Treatment.com AI, supports this model through its Global Library of Medicine (GLM), a physician-developed AI engine that is designed to assist healthcare professionals in reducing administrative tasks, onboarding, triage, and clinical decision-making. 

"AI is offering the possibility to significantly impact healthcare for the 3 Ps: the Patient, the Provider, and the Payer," said Dr. Essam Hamza, CEO of Treatment.com AI. "What Secretary Kennedy described isn't hypothetical. It's happening now."

On May 20, Treatment.com AI Inc. announced that its virtual care subsidiary, Rocket Doctor Inc., partnered with Melanoma Canada to expand access to follow-up care for patients identified during mobile skin cancer screenings. Under the agreement, individuals flagged as at-risk during Melanoma Canada's Mole Mobile campaign will be referred to Rocket Doctor physicians across Ontario, Alberta, and British Columbia using a digital intake system.

The Mole Mobile units, which offer free screenings by certified dermatologists, travel through Alberta, British Columbia, Ontario, and Quebec. For patients without a family doctor, the partnership provides an immediate pathway to care. "By partnering with Melanoma Canada, we're making it easier for patients identified during these critical screenings to get connected to a physician quickly," said Dr. Cherniak.

The initiative is expected to increase patient visits on Rocket Doctor's platform throughout the Mole Mobile tour. Skin cancer is the most common cancer in Canada, accounting for one in three cancer diagnoses. Each day, 22 Canadians are diagnosed with melanoma, and three die from the disease. The campaign will launch its 2025 season with events in Toronto and Edmonton, with further stops planned through October.

AI-Powered Healthcare: Scaling Amid Opportunity and Complexity

A report from Exploring Topics published on April 29 highlighted that 71% of U.S. healthcare industry leaders expected improved profitability in 2025, driven largely by AI-enabled automation and data efficiency. Among healthcare organizations that had implemented generative AI tools, 54% had already observed a meaningful return on investment. The report stated, "Healthcare AI searches are up 911% in the last five years," reflecting growing institutional interest in AI integration. However, 72% of healthcare organizations also expressed concern about security risks associated with the rapid advancement of AI technologies, including vulnerabilities in connected smart devices.

Artificial intelligence (AI) adoption in healthcare continued to expand across clinical, administrative, and research domains as providers sought to streamline care delivery and reduce costs. According to Techtarget on May 1, hospitals and provider organizations had integrated AI into workflows to enable more personalized treatment plans and improve communication across stakeholders. The article noted that AI-powered clinical decision support systems (CDSS) were evolving from standalone tools into deeply integrated solutions capable of analyzing both structured and unstructured data within electronic health records.

AI in Healthcare reported on May 16 that while healthtech unicorns remained rare, making up only 8% of the more than 1,000 unicorns globally, they were becoming more prominent as structural barriers began to ease. Venture capital firm SignalFire observed that healthcare startups were previously hindered by complex regulations and fragmented buyer environments but now benefitted from favorable timing and growing talent pools. "Healthcare is leapfrogging," the report stated, adding that healthtech founders were increasingly combining clinical insight with operational expertise from outside the healthcare sector.

Analyst Identifies Breakout Potential in AI Healthtech

*On May 21, Technical Analyst Clive Maund published a favorable assessment of Treatment.com AI Inc., stating that the company was "positioning to be a major play in the AI transformation of healthcare."

According to Maund, Treatment.com AI has designed a platform focused on addressing long-standing inefficiencies in the healthcare system by offering a physician-built AI platform that combines clinical intelligence, virtual care, and voice assistant technologies within a single ecosystem. He emphasized that the platform's diagnostic tools have the ability to deliver consistent, 24/7 availability and emotional responsiveness through advanced voice AI, while drawing from the company's proprietary Global Library of Medicine (GLM).

Maund also pointed to Rocket Doctor, a subsidiary of Treatment.com AI, as a scalable solution for physicians that enabled remote care delivery, describing it as "a Shopify for physicians." 

From a technical standpoint, Maund observed that the company's stock had completed a 3-wave A-B-C correction and had started to move higher from key support levels. He described the price movement as emerging from a long-term base pattern formed over the past 30 months.

"With the price just starting to advance off important support . . .  the time is believed to be at hand for the stock to advance to break out above the key resistance," Maund wrote. He identified CA$1.08 to CA$1.12 as the first price target range and CA$4.00 as the second, with additional upside possible beyond those levels.

He further highlighted the significance of the strong volume buildup since early 2024, stating that it "supports a significant new uptrend developing from here." Maund concluded that the company's market positioning and technical signals made it "an excellent time to buy or add to positions in Treatment AI.com."

Looking Ahead: Where Treatment.com AI Is Gaining Ground

Treatment.com AI's investor presentation details how the company is positioning itself at the intersection of healthcare delivery, artificial intelligence, and virtual care enablement through the integration of its GLM platform and expanding acquisition strategy. The company's AI engine (GLM), which includes over 10,000 peer-reviewed clinical entries, supports differential diagnoses, recommends lab tests (and other required tests/exams), and suggests treatment pathways — all tailored geographically, and the GLM is reviewed by credentialed medical experts. 

Rocket Doctor, acquired earlier in 2025, has grown its SaaS-based annual recurring revenue to approximately an ARR of CA$1.9 million (as at December 2024), reflecting 88% year-over-year growth from the same period in 2023. While reported in Canadian dollars, these financial figures were unaudited and included a reduction in net loss from approximately CA$2.4 million in 2023 to CA$1.3 million in 2024. The platform has been used in more than 12,500 total appointments, with an average monthly growth rate of 20%, according to the company's investor presentation from March 2025. 

Additional momentum is likely to come from Treatment.com AI's announced intent to acquire Alea Health, which expands its potential voice AI and mental health capabilities and opens channels into the Middle East healthcare market. The company's proprietary voice agent, CARA, is currently being tested for multilingual patient triage, post-discharge monitoring, and remote therapy.

In addition to its virtual care operations, Treatment.com AI is actively helping to advance medical education through strategic partnerships with leading institutions, including the University of Minnesota and the University of Edinburgh. The company's work in this space supports the development of next-generation training tools and AI-driven clinical education platforms designed to enhance diagnostic accuracy and clinical reasoning for students and healthcare professionals. To underscore the accuracy of their platform, an undergrad student (with no medical training), using a Treatment.com AI's platform, accurately diagnosed 11 out of 12 simulated patients.

Ownership and Share Structure

According to Refinitiv, insiders own approximately 5.1% of Treatment.com AI. Institutions hold .81%. Retail investors own the remaining 94.1%.   

The company has 75,502,398 million outstanding common shares.  The market cap is approximately CA$35,486,127.06.

Over the past 52 weeks, the company traded between CA$0.0471 and CA$0.9116 per share.